Advanced Gene Technologies
Selexis SGE® (Selexis Genetic Elements)
Selexis is the global leader in mammalian cell line development that leverages best-in-class protein expression technologies and modular workflows to create highly specialized solutions that enable the bio-pharmaceutical industry to streamline the drug discovery through development continuum and rapidly commercialize innovative biologic-based medicines and vaccines against diseases of high unmet need such as cancer, autoimmune and inflammatory diseases, infectious diseases, blood, metabolic and genetic disorders as well as dermatology and opthalamic (eye) diseases.
Protein Expression with the SUREtechnology PLATFORM™
Geneva, Switzerland, November 1, 2021 – Selexis SA, a JSR Life Sciences company, today announced that business and...
Just as it is well understood that silicon chips must be made in sophisticated factories with the appropriate...
Our global partners are utilizing Selexis protein expression technologies and proprietary CHO cell line to advance a pipeline of more than 140 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.